Engineered immune cells take on tough blood disorder
NCT ID NCT07091370
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This early-stage trial tests a new cell therapy called inaticabtagene autoleucel for people with a severe type of autoimmune hemolytic anemia that hasn't improved after at least three other treatments. The therapy uses a patient's own modified immune cells to target and destroy the faulty cells causing the anemia. The main goal is to check if the treatment is safe and to find the right dose, with 12 participants expected to enroll.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AIHA - COLD AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.